A
44.14
0.42 (0.96%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Avidity Biosciences, Inc. | Bullish | Bullish |
Stockmoo Score
-0.1
|
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 63.00 (Barclays, 42.73%) | Buy |
| Median | 60.00 (35.93%) | |
| Low | 45.00 (B of A Securities, 1.95%) | Buy |
| Average | 56.20 (27.32%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 43.94 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 28 Aug 2024 | 63.00 (42.73%) | Buy | 43.63 |
| Evercore ISI Group | 26 Aug 2024 | 53.00 (20.07%) | Buy | 44.18 |
| 12 Aug 2024 | 54.00 (22.34%) | Buy | 44.48 | |
| Needham | 13 Aug 2024 | 60.00 (35.93%) | Buy | 44.99 |
| 12 Jun 2024 | 46.00 (4.21%) | Buy | 38.36 | |
| Chardan Capital | 09 Aug 2024 | 60.00 (35.93%) | Buy | 46.95 |
| 12 Jun 2024 | 45.00 (1.95%) | Buy | 38.36 | |
| B of A Securities | 13 Jun 2024 | 45.00 (1.95%) | Buy | 39.96 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |